RRM1 and non-small cell lung carcinoma: Finally, non-small cell lung cancer patients with low level expression of the Ml subunit of RR (RRM1) significantly benefited from gemcitabine/cisplatin neoadjuvant chemotherapy [17], while resistance to gemcitabine was observed in cells overexpressing both RRM1 and RRM2 [18, 19].